Cargando…

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

Detalles Bibliográficos
Autor principal:	Quintás-Cardama, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057459/ https://www.ncbi.nlm.nih.gov/pubmed/30042816 http://dx.doi.org/10.18632/oncotarget.25688

Ejemplares similares

Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Intensified therapy in diffuse large B-cell lymphoma
por: Novo, Mattia, et al.
Publicado: (2017)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
por: Sheikh, Semira, et al.
Publicado: (2021)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
por: Wudhikarn, Kitsada, et al.
Publicado: (2020)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.
por: Frank, Matthew J., et al.
Publicado: (2023)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
por: Schaefer, Andrew, et al.
Publicado: (2021)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma
por: Minderman, Marthe, et al.
Publicado: (2020)

Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment
por: Pileri, Stefano A., et al.
Publicado: (2019)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
por: Paillassa, Jérôme, et al.
Publicado: (2021)

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
por: Rampotas, Alexandros, et al.
Publicado: (2021)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
por: Gambella, Massimiliano, et al.
Publicado: (2022)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
por: Lekakis, Lazaros J., et al.
Publicado: (2019)

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
por: Spanjaart, Anne M., et al.
Publicado: (2023)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
por: Zhang, Jie, et al.
Publicado: (2020)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
por: Al-Mansour, Mubarak, et al.
Publicado: (2020)

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
por: Chadha, Juskaran, et al.
Publicado: (2019)

Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD
por: Kutsch, Nadine, et al.
Publicado: (2022)

P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
por: Spanjaart, A. M., et al.
Publicado: (2022)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_adf6n539u25f5bo1vhrmopb1iv